Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

David Michael Williams, Executive Vice President and Chief Information & Digital Officer at Merck (NSE:PROR) & Co., Inc.

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers. But some of those revenues are helping British scientists ...

Merck's Keytruda (pembrolizumab) has hit the mark in the late-stage NRG-GY018 trial, with a combination of the drug plus chemotherapy improving progression-free survival (PFS) versus chemo alone ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

We live in an era when many sectors are dynamic, and one of the many that’s quite active in the past several years is the ...

Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...